MetaVia (MTVA)
NASDAQ:MTVA
Want to see MTVA full AI Analyst Report?
MTVA Stock Chart & Stats
$1.40
-$0.13(-5.60%)
At close: 4:00 PM EST
$1.40
-$0.13(-5.60%)
Day’s Range― - ―
52-Week Range$0.97 - $19.02
Previous CloseN/A
Volume36.62K
Average Volume (3M)3.42M
Market Cap
$8.99M
Enterprise Value-$9.90M
Total Cash (Recent Filing)$13.73M
Total Debt (Recent Filing)$194.00K
Price to Earnings (P/E)―
Beta1.43
Next Earnings
Aug 18, 2026EPS Estimate
-0.82Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-6.03
Shares Outstanding5,164,370
10 Day Avg. Volume118,677
30 Day Avg. Volume3,419,960
Financial Highlights & Ratios
PEG Ratio0.01
Price to Book (P/B)2.79
Price to Sales (P/S)0.00
P/FCF Ratio-0.95
Enterprise Value/Market Cap-1.10
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit660.31
Enterprise Value/Ebitda0.76
Forecast
1Y Price Target
$14.00Price Target Upside900.00% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-2.48
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical Efficacy Of DA-1726 (Phase 1)Robust Phase 1 efficacy (9.1% mean weight loss at 48 mg) with favorable safety and metabolic improvements supports durable clinical differentiation versus many GLP-1s. This improves odds for partnerships, later-stage trial design and regulatory interest, strengthening long-term development prospects for obesity and MASH.
Low Financial LeverageVery low debt reduces fixed financial obligations and preserves strategic flexibility for a capital-intensive biotech. With limited leverage, MetaVia can pursue clinical programs or collaborations without immediate creditor pressure, helping preserve optionality during multi-year development timelines.
Differentiated Pipeline With Combination PotentialVanoglipel's preclinical synergy with established agents and DA-1726's dual agonist mechanism broaden therapeutic applications across MASH, T2D and obesity. Pipeline versatility increases commercial and partnering pathways, enabling modular development strategies and multiple potential value inflection points beyond a single asset outcome.
Bears Say
Pre-revenue With Persistent Net LossesBeing pre-revenue with recurring, material net losses means MetaVia must rely on external funding until commercialization. Persistent losses reflect an R&D cost structure without offsetting revenues, increasing dilution risk and making long-term success contingent on clinical and regulatory milestones.
Significant And Ongoing Cash BurnSustained negative operating and free cash flows indicate the company is not self-funding development. Continued cash burn raises the probability of near- to medium-term financings, which can dilute shareholders and divert management focus toward capital raises rather than execution of clinical programs.
Limited Cash Runway And Small OrganizationModest cash on hand and a nine-person staff limit the company's ability to scale trials, commercial planning, or in-house development. Tight runway through late 2026 increases dependency on timely clinical readouts, partnerships or financings to avoid program delays or resource constraints that could slow long-term progress.
MetaVia News
MTVA FAQ
What was MetaVia’s price range in the past 12 months?
MetaVia lowest stock price was $0.97 and its highest was $19.02 in the past 12 months.
What is MetaVia’s market cap?
MetaVia’s market cap is $8.99M.
When is MetaVia’s upcoming earnings report date?
MetaVia’s upcoming earnings report date is Aug 18, 2026 which is in 62 days.
How were MetaVia’s earnings last quarter?
MetaVia released its earnings results on May 14, 2026. The company reported -$0.79 earnings per share for the quarter, missing the consensus estimate of -$0.743 by -$0.047.
Is MetaVia overvalued?
According to Wall Street analysts MetaVia’s price is currently Undervalued.
Does MetaVia pay dividends?
MetaVia does not currently pay dividends.
What is MetaVia’s EPS estimate?
MetaVia’s EPS estimate is -0.82.
How many shares outstanding does MetaVia have?
MetaVia has 5,164,370 shares outstanding.
What happened to MetaVia’s price movement after its last earnings report?
MetaVia reported an EPS of -$0.79 in its last earnings report, missing expectations of -$0.743. Following the earnings report the stock price went down -6.723%.
Which hedge fund is a major shareholder of MetaVia?
Currently, no hedge funds are holding shares in MTVA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
MetaVia
Headquartered in Cambridge, Massachusetts, MetaVia Inc. operates as a clinical-stage biotechnology company with a core focus on discovering and commercializing novel pharmaceutical solutions for cardiometabolic disorders. Its leading investigational drug, DA-1241, a unique G-Protein-Coupled Receptor 119 agonist, is currently undergoing Phase 2a clinical trials for metabolic dysfunction-associated steatohepatitis (MASH). This follows the successful completion of Phase 1 trials for type 2 diabetes mellitus (T2DM), and the compound holds promise for use as both a standalone therapy and in combination treatments. Another significant asset, DA-1726, an innovative oxyntomodulin analogue that functions as a dual agonist for GLP-1 and glucagon receptors, is presently in preclinical development specifically for treating obesity. MetaVia's broader therapeutic pipeline also includes ANA001, a distinct oral niclosamide formulation intended for moderate COVID-19 patients; NB-01, designed to address painful diabetic neuropathy; NB-02, targeting cognitive impairment; and Gemcabene, for the management of dyslipidemia. The company engages in strategic partnerships, notably a licensing agreement with Pfizer Inc. for the research, development, manufacturing, and commercialization of Gemcabene. Additionally, a joint research collaboration with Dong-A ST and ImmunoForge supports the advancement of DA-1726. The entity adopted its current name, MetaVia Inc., in November 2024, transitioning from its former identity as NeuroBo Pharmaceuticals, Inc.
MTVA Stock 12 Month Forecast
Average Price Target
$14.00
▲(900.00% Upside)
Technical Analysis
Ownership Overview
3.77% Insiders
0.27% Mutual Funds
0.19% Other Institutional Investors
95.72% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---